Open Access

ARTICLE

Pan-cancer analysis of RNA 5-methylcytosine reader (ALYREF)

by XING YE^1,#, ZHOUTING TUO^2,#, KAI CHEN³, RUICHENG WU³, JIE WANG³, QINGXIN YU⁴, LUXIA YE⁵, AKIRA MIYAMOTO⁶, KOO HAN YOO⁷, CHI ZHANG⁸, WURAN WEI³, DENGXIONG LI^3,*, DECHAO FENG^3,*

1 Samuel Oschin Comprehensive Cancer Institute, Department of Medicine, Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, 90048, USA
2 Department of Urology, The Second Affiliated Hospital of Anhui Medical University, Hefei, 230601, China
3 Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, 610041, China
4 Department of Pathology, Ningbo Diagnostic Pathology Center, Ningbo, 315021, China
5 Department of Public Research Platform, Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University, Linhai, 317000, China
6 Department of Rehabilitation, West Kyushu University, Kanzaki-shi, 842-8585, Japan
7 Department of Urology, Kyung Hee University, Seoul, 446 701, South Korea
8 Department of Rehabilitation, The Affiliated Hospital of Southwest Medical University, Luzhou, 646000, China

* Corresponding Authors: DENGXIONG LI. Email: ; DECHAO FENG. Email: ,
# These authors contributed equally to this work

Oncology Research 2024, 32(3), 503-515. https://doi.org/10.32604/or.2024.045050

Received 16 August 2023; Accepted 01 December 2023; Issue published 06 February 2024

Abstract

The increasing interest in RNA modifications has significantly advanced epigenomic and epitranscriptomic technologies. This study focuses on the immuno-oncological impact of ALYREF in human cancer through a pan-cancer analysis, enhancing understanding of this gene’s role in cancer. We observed differential ALYREF expression between tumor and normal samples, correlating strongly with prognosis in various cancers, particularly kidney renal papillary cell carcinoma (KIRP) and liver hepatocellular carcinoma (LIHC). ALYREF showed a negative correlation with most tumor-infiltrating cells in lung squamous cell carcinoma (LUSC) and lymphoid neoplasm diffuse large B-cell lymphoma (DLBC), while positive correlations were noted in LIHC, kidney chromophobe (KICH), mesothelioma (MESO), KIRP, pheochromocytoma and paraganglioma (PARD), and glioma (GBMLGG). Additionally, ALYREF expression was closely associated with tumor heterogeneity, stemness indices, and a high mutation rate in TP53 across these cancers. In conclusion, ALYREF may serve as an oncogenic biomarker in numerous cancers, meriting further research attention.

---

Keywords

---